Advertisement
AMRX vs PRFX
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMRX is a StrongBuy and PRFX is a Buy.
Momentum Indicator for AMRX turns positive, indicating new upward trend
AMRX saw its Momentum Indicator move above the 0 level on October 21, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 84 similar instances where the indicator turned positive. In 71 of the 84 cases, the stock moved higher in the following days. The odds of a move higher are at 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The 10-day moving average for AMRX crossed bullishly above the 50-day moving average on September 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 80%.
Following a +3.23% 3-day Advance, the price is estimated to grow further. Considering data from situations where AMRX advanced for three days, in 245 of 299 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
AMRX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The 10-day RSI Indicator for AMRX moved out of overbought territory on September 29, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 43 similar instances where the indicator moved out of overbought territory. In 31 of the 43 cases, the stock moved lower in the following days. This puts the odds of a move lower at 72%.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The Moving Average Convergence Divergence Histogram (MACD) for AMRX turned negative on October 08, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 25 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 57%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AMRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 68%.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 7 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. AMRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 100 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: AMRX's P/B Ratio (215.998) is very high in comparison to the industry average of (10.407). P/E Ratio (40.960) is within average values for comparable stocks, (-6.173). Projected Growth (PEG Ratio) (1.947) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.037) among similar stocks. P/S Ratio (1.899) is also within normal values, averaging (178.797).
PRFX's RSI Indicator climbs out of oversold territory
The RSI Oscillator for PRFX moved out of oversold territory on October 21, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 52 similar instances when the indicator left oversold territory. In 48 of the 52 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 17 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +2.38% 3-day Advance, the price is estimated to grow further. Considering data from situations where PRFX advanced for three days, in 152 of 184 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
PRFX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PRFX as a result. In 97 of 99 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for PRFX turned negative on October 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 52 similar instances when the indicator turned negative. In 51 of the 52 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PRFX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for PRFX entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 34 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.168) is normal, around the industry mean (11.138). P/E Ratio (-0.187) is within average values for comparable stocks, (-7.600). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.038) among similar stocks. P/S Ratio (34.722) is also within normal values, averaging (178.797).
The Tickeron Price Growth Rating for this company is 92 (best 1 - 100 worst), indicating slightly worse than average price growth. PRFX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PRFX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
AMRX | PRFX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 14 | 9 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 100 Overvalued | 34 Fair valued | |
PROFIT vs RISK RATING 1..100 | 7 | 100 | |
SMR RATING 1..100 | 99 | 98 | |
PRICE GROWTH RATING 1..100 | 37 | 92 | |
P/E GROWTH RATING 1..100 | 96 | 100 | |
SEASONALITY SCORE 1..100 | 50 | 11 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
PRFX's Valuation (34) in the null industry is significantly better than the same rating for AMRX (100) in the Pharmaceuticals Major industry. This means that PRFX’s stock grew significantly faster than AMRX’s over the last 12 months.
AMRX's Profit vs Risk Rating (7) in the Pharmaceuticals Major industry is significantly better than the same rating for PRFX (100) in the null industry. This means that AMRX’s stock grew significantly faster than PRFX’s over the last 12 months.
PRFX's SMR Rating (98) in the null industry is in the same range as AMRX (99) in the Pharmaceuticals Major industry. This means that PRFX’s stock grew similarly to AMRX’s over the last 12 months.
AMRX's Price Growth Rating (37) in the Pharmaceuticals Major industry is somewhat better than the same rating for PRFX (92) in the null industry. This means that AMRX’s stock grew somewhat faster than PRFX’s over the last 12 months.
AMRX's P/E Growth Rating (96) in the Pharmaceuticals Major industry is in the same range as PRFX (100) in the null industry. This means that AMRX’s stock grew similarly to PRFX’s over the last 12 months.
| AMRX | PRFX | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 72% | 2 days ago 90% |
| Stochastic ODDS (%) | 1 day ago 75% | 2 days ago 90% |
| Momentum ODDS (%) | 1 day ago 85% | 2 days ago 90% |
| MACD ODDS (%) | 1 day ago 57% | 2 days ago 90% |
| TrendWeek ODDS (%) | 1 day ago 83% | 2 days ago 90% |
| TrendMonth ODDS (%) | 1 day ago 83% | 2 days ago 90% |
| Advances ODDS (%) | 1 day ago 82% | 8 days ago 83% |
| Declines ODDS (%) | 9 days ago 68% | 3 days ago 90% |
| BollingerBands ODDS (%) | 1 day ago 81% | 2 days ago 89% |
| Aroon ODDS (%) | N/A | 2 days ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AMRX’s FA Score shows that 1 FA rating(s) are green while PRFX’s FA Score has 0 green FA rating(s).
- AMRX’s FA Score: 1 green, 4 red.
- PRFX’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AMRX’s TA Score shows that 6 TA indicator(s) are bullish while PRFX’s TA Score has 4 bullish TA indicator(s).
- AMRX’s TA Score: 6 bullish, 4 bearish.
- PRFX’s TA Score: 4 bullish, 4 bearish.
Price Growth
AMRX (@Pharmaceuticals: Generic) experienced а +6.88% price change this week, while PRFX (@Pharmaceuticals: Generic) price change was -7.03% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -2.94%. For the same industry, the average monthly price growth was -9.84%, and the average quarterly price growth was +9.53%.
Reported Earning Dates
AMRX is expected to report earnings on Nov 03, 2026.
PRFX is expected to report earnings on Nov 19, 2026.
Industries' Descriptions
@Pharmaceuticals: Generic (-2.94% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
Advertisement
AMRX and
Correlation & Price change
A.I.dvisor indicates that over the last year, AMRX has been loosely correlated with AMPH. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if AMRX jumps, then AMPH could also see price increases.
| Ticker / NAME | Correlation To AMRX | 1D Price Change % | ||
|---|---|---|---|---|
| AMRX | 100% | +1.39% | ||
| AMPH - AMRX | 45% Loosely correlated | -0.61% | ||
| VTRS - AMRX | 43% Loosely correlated | +0.16% | ||
| ANIP - AMRX | 39% Loosely correlated | +2.09% | ||
| TEVA - AMRX | 38% Loosely correlated | -1.01% | ||
| COLL - AMRX | 34% Loosely correlated | +2.55% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| MBBA | 47.86 | 0.39 | +0.82% |
| iShares Mortgage-Backed Securities Active ETF (MBBA) | |||
| RFCI | 21.70 | 0.08 | +0.37% |
| ALPS Dynamic Core Income ETF (RFCI) | |||
| CPSM | 29.74 | N/A | N/A |
| Calamos S&P 500 Structured Alt Protection ETF (CPSM) | |||
| CANC | 41.50 | -0.03 | -0.08% |
| Tema Oncology ETF (CANC) | |||
| EWT | 103.99 | -5.00 | -4.59% |
| iShares MSCI Taiwan ETF (EWT) | |||